Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Pfizer, Haleon
Pfizer to sell about $3.25 billion stake in Sensodyne-maker Haleon, bookrunner says
Pfizer's stake sale in British consumer healthcare company Haleon has been upsized by 100 million shares to 640 million shares worth about $3.25 billion with strong demand from investors, a bookrunner familiar with the offering said on Monday.
Pfizer to Pare Back Haleon Stake With 540 Million Share Offering
Pfizer Inc. plans to sell 540 million worth of shares in Haleon Plc, as it pares back its holding in the UK consumer health giant.
Pfizer Intends to Sell Around 540 Million Ordinary Shares in Haleon -- Update
Pfizer said it intends to sell around 540 million ordinary shares in British consumer-healthcare business Haleon, or about 5.9% of the company's issued share capital. The pharmaceutical giant said Monday that the price per share will be determined by way of an accelerated bookbuilding process to institutional investors.
Pfizer to offload about 5.9% stake in UK's Haleon, says bookrunner
Pfizer intends to offload about 540 million shares in the British consumer healthcare company Haleon, a bookrunner said on Monday. The proposed sale will reduce the top shareholder's interest in Sensodyne-maker Haleon to 16.
Pfizer to sell about $3.25 bln stake in Sensodyne-maker Haleon, bookrunner says
Sept 30 (Reuters) - Pfizer's stake sale in British consumer healthcare company Haleon has been upsized by 100 million shares to 640 million shares worth about $3.25 billion with strong demand from investors, a bookrunner familiar with the offering said on Monday.
6h
Pfizer to offload about 6% stake in Sensodyne-maker Haleon, says bookrunner
Pfizer intends to sell about 540 million shares in British consumer healthcare company Haleon , a bookrunner said on Monday, ...
14h
Pfizer starts voluntary withdraw of OXBRYTA, benefit does not outweigh risks
Pfizer withdraws OXBRYTA after post marketing studies showed that the risks of side effects were greater than the benefits.
bovnews
5h
Pfizer Inc (PFE) Stock Dilemma: A Surge That Has Everyone Talking—What’s the Real Story?
On Friday, Pfizer Inc (PFE) stock saw a modest uptick, ending the day at $29.09 which represents a slight increase of $0.12 or 0.41% from the prior close of $28.97. The stock opened at $29.02 and ...
Medscape
15h
Pfizer's Withdrawal of SCD Drug Raises Questions
Pfizer withdrew its pill for sickle cell disease amid heightened European scrutiny, triggered by death rates seen in clinical ...
STAT
4d
Pharmalittle: We’re reading about Pfizer pulling a sickle cell pill, Moderna getting scolded, and more
Pfizer is removing its Oxbryta pill for sickle cell disease from all markets globally due to safety risks, including deaths.
4d
Slow progress on Pfizer's plan to sell drugs to low-income nations at not-for-profit price, says CEO
Pfizer has so far signed up less than a quarter of the countries targeted under a plan to make its medicines available to the ...
4d
Can Pfizer Stock Rise 2x To $60?
Although it has been plagued by multiple issues, including falling sales with lower demand for its Covid-19 products, and an ...
7h
Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses
CSL and Arcturus Therapeutics report that their sa-mRNA COVID-19 vaccine, ARCT-154, delivered superior immunogenicity ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Haleon
OXBRYTA
vaccine
New York Stock Exchange
Covid-19
Feedback